The FDA has approved capivasertib (Truqap™, AstraZeneca Pharmaceuticals) in combination with fulvestrant for adult patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative locally advanced or metastatic breast cancer. This indication is for patients with one or more PIK3CA/AKT1/PTEN alterations, as dete...

Oncology Data Advisor® · Real-World Use Patterns, Effectiveness, & Tolerability of Sacituzumab Govitecan for TNBC At this year's European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, Dr. Kevin Kalinsky, Director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University, presented the results ...

Oncology Data Advisor® · Reframing the Conversation in Metastatic Breast Cancer With Janie Metsker, RN, BSN, CN-BN For patients with metastatic breast cancer (MBC), Breast Cancer Awareness Month can sometimes be demoralizing in light of pervasive public messaging about finding a cure and embracing survivorship. In this interview, Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at St. Luke's Koontz Center for Advanced Breast Cancer, shares ways to reframe the conversation in metastatic breast cancer to prioritize shared decision making, patients' individual goals, and redefining hope. Additionally, we hear a message from Justin Bray, a patient with metastatic breast cancer, about the importance for clinicians to form relationships with patients in order to understand and develop the best care for them throughout their journey.  

For patients with metastatic breast cancer (MBC), Breast Cancer Awareness Month can sometimes be demoralizing in light of pervasive public messaging about finding a cure and embracing survivorship. In this interview, Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at St. Luke's Koontz Center for Advanced Breast Cancer, shares ways to reframe the conversation in metastatic breast cancer to prioritize shared decision making, patients' individual goals, and redefining hope. Additionally, we hear a message from Justin Bray, a patient with metastatic breast cancer, about the importance for clinicians to form relationships with patients in order to understand and develop the best care for them throughout their journey.  

At this year's European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, Dr. Kevin Kalinsky, Director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University, presented the results of real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line or later treatment of metast...

Oncology Data Advisor® · Self-Management Strategies for Peripheral Neuropathy With Connie Visovsky, PhD, RN, ACNP, FAAN In this interview for Breast Cancer Awareness Month, Dr. Connie Visovsky, Professor and Endowed Chair in Nursing Science at the University of South Florida, shares her research regarding exercise as a self-management st...

Oncology Data Advisor® · Breast Cancer Awareness Month: Debunking Breast Cancer Myths With Jason Mouabbi, MD In this interview for Breast Cancer Awareness Month, Dr. Jason Mouabbi, Assistant Professor in the Department of Breast Oncology at the University of Texas MD Anderson Cancer Center, provides insightful answers to frequently asked questions and debunks common myths surrounding breast cancer diagnosis, screening, and treatment.  

Oncology Data Advisor® · Pink Fund: Financial Assistance During Breast Cancer Treatment With Founder Molly MacDonald For individuals with breast cancer, financial toxicity is a significant and often overwhelming part of the fight. Pink Fund is an organization which provides 90-day non-medical cost-of-living expenses, including housing, transportation, utilities, and insurance costs, for patients undergoing active treatment for breast cancer, enabling them to focus on healing before returning to the workplace. In this interview, Pink Fund's Founder, Molly MacDonald, shares the story of how she founded the organization, resources for both patients who are experiencing financial toxicity and for clinicians seeking to support their patients, and crucial messages for raising awareness of financial toxicity during cancer treatment.  

In this interview for Breast Cancer Awareness Month, Dr. Connie Visovsky, Professor and Endowed Chair in Nursing Science at the University of South Florida, shares her research regarding exercise as a self-management strategy for chemotherapy-induced peripheral neuropathy (CIPN) experienced by patients during breast cancer treatment. Additionally, she gives an update on her presentation from last year's ODACon Breast Cancer Symposium regarding new directions in research for CDK4/6 inhibitors.  

In this interview for Breast Cancer Awareness Month, Dr. Jason Mouabbi, Assistant Professor in the Department of Breast Oncology at the University of Texas MD Anderson Cancer Center, provides insightful answers to frequently asked questions and debunks common myths surrounding breast cancer diagnosis, screening, and treatment.  

For individuals with breast cancer, financial toxicity is a significant and often overwhelming part of the fight. Pink Fund is an organization which provides 90-day non-medical cost-of-living expenses, including housing, transportation, utilities, and insurance costs, for patients undergoing active treatment for breast cancer, enabling them to focus on healing before returning to the workplace. In this interview, Pink Fund's Founder, Molly MacDonald, shares the story of how she founded the organization, resources for both patients who are experiencing financial toxicity and for clinicians seeking to support their patients, and crucial messages for raising awareness of financial toxicity during cancer treatment.  

Oncology Data Advisor® · Impact of Social Determinants of Health on TNBC Treatment With Nicholas Robert, MD In this interview from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor speaks with Dr. Nicholas Robert, Chief Medical Officer for Ontada, about his team's abstract regarding the impacts of social determinants of health on genetic testing and treatment selection in triple-negative breast cancer (TNBC).  

Oncology Data Advisor® · Expert Perspectives in the Management of Triple-Negative Breast Cancer:Webinar Preview, Sara Tolaney i3 Health recently hostedPathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer (TNBC): Case Explorations and Answers to FAQs, an accredited CME/NCPD webinar now available on...

i3 Health recently hosted Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer (TNBC): Case Explorations and Answers to FAQs, an accredited CME/NCPD webinar now available on the i3 Health website. In this video interview, Dr. Tolaney shares a preview of the important topics discussed in the activity, includi...

Oncology Data Advisor® · Developing Telegenetic Cancer Risk Assessment for Black Individuals With Darya Kizub, MD At the recent 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Darya Kizub, Hematology-Oncology Fellow at MD Anderson Cancer Center, presented her team's research regarding a novel initiative for recruiting Black individuals to be screened for hereditary cancer genetic testing eligibility. Prior to presenting, she sat down with Oncology Data Advisor to share more about the need to provide cancer genetic testing for Black individuals and the ways that she and her team have partnered with the community to enact this change.  

In 2006, after being diagnosed with breast cancer at the age of 32, Maimah Karmo decided to dedicate herself to empowering women with breast cancer to serve as advocates for themselves, resulting in the creation of Tigerlily Foundation. In this interview, Ms. Karmo shares more of her story and her passion for amplifying the patient's voice, increas...

Oncology Data Advisor® · Social Media’s Effect on Informed Decision Making in Cancer Treatment Welcome to Oncology Data Advisor®, a digital resource for the multidisciplinary cancer team. In this podcast episode, Nina Morena, MA, PhD Candidate at McGill University, and Ari Meguerditchian, MD, Surgical Oncologist at McGill Universit...

Oncology Data Advisor® · Social Determinants of Health and Genetic Testing in Triple-Negative Breast Cancer: Barb Kunz, LCGC At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor® sat down with Barb Kunz, a Senior Genetic Counselor at the US Oncology Network, to talk about her research on rates of germline testing for BRCA1 and BRCA2 mutations in patients with triple-negative breast cancers and her presentation on the impacts of social determinants of health on genetic testing.  

Phosphatidylinositol-3-kinase (PI3K) inhibitors are effective treatment for patients with breast cancer but can be associated with significant hyperglycemia and rash. In this interview from the 48th Annual Oncology Nursing Society (ONS) Congress, Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at St. Luke's Koontz Center for Advanced Breast Cancer, shares updated strategies for managing these toxicities in order to provide the best outcomes for patients with breast cancer receiving PI3K inhibitors.  

Eun-Ok Im, PhD, MPH, RN, CNS, FAAN, was recently named as the recipient of the 2023 Oncology Nursing Society (ONS) Distinguished Nurse Researcher Award. At this past ONS Congress, Dr. Im gave a presentation on her pioneering use of technology and Internet-based approaches to address racial and ethnic survivorship disparities in the cancer survivorship experience, which she has been among the first to research over the course of her career. In this interview, she provides the background behind this approach and how it has been used to improve survivorship experience for racial/ethnic minority cancer patients.